CAJ | 학술논문

目的探索辅助性干扰素治疗对根治性切除术后乙肝相关性肝癌的临床效果.方法检索2000年1至月2013年1月网络数据库中有关干扰素对乙肝相关性原发性肝癌根治性切除术后的临床试验.结果通过筛选共有5项临床试验、694例患者纳入分析.干扰素组和对照组原发性肝癌患者术后1、2、3、5年总生存率的比值比及95％可信区间(95％ CI)分别为:3.37(1.18 ～6.27,P =0.000)、2.36(1.45 ～3.83,P=0.001)、1.81(1.21～2.72,P=0.004)和1.93(1.35～2.75,P=0.000);术后第1、2、3、5年复发率的比值比(95％ CI)为:0.63(0.44～ 0.91,P=0.014)、0.84(0.60 ～ 1.18,P=0.322)、0.88(0.63 ～ 1.22,P=0.431)和0.78(0.56 ～1.07,P=0.120).结论辅助性干扰素治疗可提高肝癌患者术后总体生存率,但对肝癌术后复发率无明显作用.
목적 탐색보조성간우소치료대근치성절제술후을간상관성간암적림상효과.방법 검색2000년1지월2013년1월망락수거고중유관간우소대을간상관성원발성간암근치성절제술후적림상시험.결과 통과사선공유5항림상시험、694례환자납입분석.간우소조화대조조원발성간암환자술후1、2、3、5년총생존솔적비치비급95％가신구간(95％ CI)분별위:3.37(1.18 ～6.27,P =0.000)、2.36(1.45 ～3.83,P=0.001)、1.81(1.21～2.72,P=0.004)화1.93(1.35～2.75,P=0.000);술후제1、2、3、5년복발솔적비치비(95％ CI)위:0.63(0.44～ 0.91,P=0.014)、0.84(0.60 ～ 1.18,P=0.322)、0.88(0.63 ～ 1.22,P=0.431)화0.78(0.56 ～1.07,P=0.120).결론 보조성간우소치료가제고간암환자술후총체생존솔,단대간암술후복발솔무명현작용.
Objective To assess the efficacy of postoperative adjuvant interferon (IFN) therapy on patients with hepatitis B virus (HBV) related hepatocellular carcinoma (HCC).Methods An electronic search for articles published from January 2000 to January 2013 was conducted to identify English language comparative studies evaluating IFN therapy on recurrence and survival after surgical treatment of HCC.Results A total of five trials consisting of 694 patients were included in the Meta-analysis.The estimated odds ratios (OR) for the 1-,2-,3-,and 5-year overall survival rates of HBV-related HCC were 3.37 (95％CI:1.18-6.27,P=0.000),2.36 (95％ CI:1.45-3.83,P=0.001),1.81 (95％ CI:1.21-2.72,P=0.004),and 1.93 (95％ CI:1.35-2.75,P=0.000),respectively.The OR for the 1-,2-,3-,and 5-year recurrence rates were 0.63 (95％ CI:0.44-0.91,P=0.014),0.84 (95％ CI:0.60-1.18,P=0.322),0.88 (95％ CI:0.63-1.22,P=0.431),and 0.78 (95％ CI:0.56-1.07,P=0.120),respectively.Conclusion This Meta-analysis shows that IFN therapy had a significant clinical effect in improving overall survival rates but not in decreasing recurrence rates of HBV infected HCC patients postoperatively.